2021
DOI: 10.1016/j.wneu.2021.08.142
|View full text |Cite
|
Sign up to set email alerts
|

Dose Adjustment Associated Complications of Bone Morphogenetic Protein: A Longitudinal Assessment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 19 publications
0
3
0
Order By: Relevance
“…In the future, the use of single factor assembled bioengineered materials will gradually decrease. This can create physiological disorders, such as the use of biomaterials to deliver BMP‐2 beyond the physiological dose to anterior spinal fusion, which can cause more complications than traditional autologous bone grafting 32 …”
Section: Discussionmentioning
confidence: 99%
“…In the future, the use of single factor assembled bioengineered materials will gradually decrease. This can create physiological disorders, such as the use of biomaterials to deliver BMP‐2 beyond the physiological dose to anterior spinal fusion, which can cause more complications than traditional autologous bone grafting 32 …”
Section: Discussionmentioning
confidence: 99%
“…However, several severe adverse events have been reported and the majority are believed to be a consequence of applying supra-physiological doses to the defect area [ 10 ]. Indeed, a meta-analysis indicates that the reduction of the rhBMP-2 dose correlates with a lower complication rate after performing a spinal fusion procedure [ 20 ]. Therefore, scaffold-based strategies to enhance the efficacy of rhBMP-2, and hence resulting in a reduction of the therapeutic dose required, represent an attractive modality to improve the overall safety profile.…”
Section: Discussionmentioning
confidence: 99%
“…Many studies have demonstrated the utility of recombinant human BMP-2 (rhBMP-2) in enhancing fusion rates, so the use of rhBMP-2 has expanded in an off-label manner for various spinal fusion surgeries to assist with fusion in severe osteoporosis patients. However, there is a significant relation between the dose of rhBMP-2 use and the complication rates [ 8 ]. Concerns about postoperative complications of use of rhBMP-2 is a challenging issue of spine field, so more studies are needed.…”
mentioning
confidence: 99%